The protein expression of TRP-1 and galectin-1 in cutaneous malignant melanomas

Cancer Genomics and Proteomics

Volumn 5, Issue 6, 2008, Pages 293-300

  Bolander, Åsa ^a   Agnarsdóttir, Margrét ^b   Strömberg, Sara ^b   Ponten, Fredrik ^b   Hesselius, Patrik ^a   Uhlen, Mathias ^c   Bergqvist, Michael ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ALBANOVA UNIVERSITY CENTER   (Sweden)

Author keywords

Galectin 1; Human Protein Atlas Program; Malignant melanoma; TRP 1

Indexed keywords

GALECTIN 1; GLYCOPROTEIN; KI 67 ANTIGEN; MELAN A; MOLECULAR MARKER; PROTEIN ANTIBODY; PROTEIN TRP 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MELANOMA; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SKIN CARCINOGENESIS; TISSUE MICROARRAY;

EID: 58249106935     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Armstrong BK and Kricker A: Cutaneous melanoma. Cancer Surv 19-20: 219-240, 1994.
2. Hamre MR, Chuba P, Bakhshi S, Thomas R and Severson RK: Cutaneous melanoma in childhood and adolescence. Pediatr Hematol Oncol 19: 309-317, 2002.
3. Karlsson P, Boeryd B, Sander B, Westermark P and Rosdahl I: Increasing incidence of cutaneous malignant melanoma in children and adolescents 12-19 years of age in Sweden 1973-92. Acta Derm Venereol 78: 289-292, 1998.
4. Lange JR and Balch CM: Melanoma in children: heightened awareness of an uncommon but often curable malignancy. Pediatrics 115: 802-803, 2005.
5. Strouse JJ, Fears TR, Tucker MA and Wayne AS: Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol 23: 4735-4741, 2005.
6. Wong AK and Chin L: An inducible melanoma model implicates a role for RAS in tumor maintenance and angiogenesis. Cancer Metastasis Rev 19: 121-129, 2000.
7. Uhlen M and Ponten F: Antibody-based proteomics for human tissue profiling. Mol Cell Proteomics 4: 384-393, 2005.
8. Uhlen M, Bjorling B, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, Berglund L, Bergstrom K, Brumer H, Cerjan D, Ekstrom M, Elobeid A, Eriksson C, Fagerberg L, Falk R, Fall J, Forsberg M, Bjorklund MG, Gumbel K, Halimi A, Hallin I, Hamsten C, Hansson M, Hedhammar M, Hercules G, Kampf C, Larsson K, Lindskog M, Lodewyckx W, Lund J, Lundeberg J, Magnusson K, Malm E, Nilsson P, Odling J, Oksvold P, Olsson I, Oster E, Ottosson J, Paavilainen L, Persson A, Rimini R, Rockberg J, Runeson M, Sivertsson A, Skollermo A, Steen J, Stenvall M, Sterky F, Stromberg S, Sundberg M, Tegel H, Tourle S, Wahlund E, Walden A, Wan J, Wernerus H, Westberg J, Wester K, Wrethagen U, Xu LL, Hober S and Ponten F: A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 4: 1920-1932, 2005.
9. Nilsson P, Paavilainen L, Larsson K, Odling J, Sundberg M, Andersson AC, Kampf C, Persson A, Al-Khalili Szigyarto C, Ottosson J, Bjorling E, Hober S, Wernerus H, Wester K, Ponten F and Uhlen M: Towards a human proteome atlas: high-throughput generation of mono-specific antibodies for tissue profiling. Proteomics 5: 4327-4337, 2005.
10. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998.
11. Kampf C, Wester K, Björling E, Uhlen M, and Ponten F.: Antibody-based tissue profiling as a tool for clinical proteomics. Clin Proteomics 1: 285-299, 2004.
12. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, Leffler H, Liu FT, Lotan R, Mercurio AM, Monsigny M, Pillai S, Poirer F, Raz A, Rigby P, Rini J and Wang JL Galectins: a family of animal beta-galactoside-binding lectins. Cell 76: 597-598, 1994.
13. Chung CD, Patel VP, Moran M, Lewis LA and Miceli MC: galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction. J Immunol 165: 3722-3729, 2000.
14. Moiseeva EP, Javed Q, Spring EL and de Bono DP: Galectin 1 is involved in vascular smooth muscle cell proliferation. Cardiovasc Res 45: 493-502, 2000.
15. Camby I, Mercier ML, Lefranc F and Kiss R: galectin-1: A Small Protein with Major Functions. Glycobiology 16: 137-157, 2006.
16. Vijayasaradhi S, Doskoch PM and Houghton AN: Biosynthesis and intracellular movement of the melanosomal membrane glycoprotein gp75, the human b (brown) locus product. Exp Cell Res 196: 233-240, 1991.
17. Vijayasaradhi S, Bouchard B and Houghton AN: The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 171: 1375-1380, 1990.
18. Jimbow K, Gomez PF, Toyofuku K, Chang D, Miura S, Tsujiya H and Park JS: Biological role of tyrosinase related protein and its biosynthesis and transport from TGN to stage I melanosome, late endosome, through gene transfection study. Pigment Cell Res 10: 206-213, 1997.
19. Hazan C, Melzer K, Panageas KS, Li E, Kamino H, Kopf A, Cordon-Cardo C, Osman I and Polsky D: Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. Cancer 95: 634-640, 2002.
20. Alonso SR, Ortiz P, Pollan M, Perez-Gomez B, Sanchez L, Acuna MJ, Pajares R, Martinez-Tello FJ, Hortelano CM, Piris MA and Rodriguez-Peralto JL: Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 164: 193-203, 2004.
21. Li CY, Gao TW, Wang G, Han ZY, Shen Z, Li TH and Liu YF: The effect of antisense tyrosinase-related protein 1 in melanocytes and malignant melanoma cells. Br J of Dermatology 150: 1081-1090, 2004.
22. Nylander K, Bourdon JC, Bray SE, Gibbs NK, Kay R, Hart I and Hall PA: Transcriptional activation of tyrosinase and TRP-1 by p53 links UV irradiation to the protective tanning response. J Pathol 190: 39-46, 2000.
23. Paron I, D'Ambrosio C, Scaloni A, Berlingieri MT, Pallante PL, Fusco A, Bivi N, Tell G and Damante G: A differential proteomic approach to identify proteins associated with thyroid cell transformation. J Mol Endocrinol 34: 199-207, 2005.
24. Berberat PO, Friess H, Wang L, Thu Z, Bley T, Frigeri L, Zimmermann A and Buchler MW: Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J Histochem Cytochem 49: 539-549, 2001.
25. Fitzner B, Walzel H, Sparmann G, Emmrich J, Liebe S and Jaster R: galectin-1 is an inductor of pancreatic stellate cell activation. Cell Signal 17: 1240-1247, 2005.
26. Cindolo L, Benvenuto G, Salvatore P, Pero R, Salvatore G, Mirone V, Prezioso D, Altieri V, Bruni CB and Chiariotti L: galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Int J Cancer 84: 39-43, 1999.
27. Horiguchi N, Arimoto K, Mizutani A, Endo-Ichikawa Y, Nakada H and Taketani S: galectin-1 induces cell adhesion to the extracellular matrix and apoptosis of non-adherent human colon cancer Colo201 cells. J Biochem (Tokyo) 134: 869-874, 2003.
28. Gabius HJ, Andre S, Gunsenhauser I, Kaltner H, Kayser G, Kopitz J, Lahm H, Harms D, Szymas J and Kayser K: Association of galectin-1- but not galectin-3-dependent parameters with proliferation activity in human neuroblastomas and small cell lung carcinomas. Anticancer Res 22: 405-410, 2002.
29. van den Brule FA, Waltregny D and Castronovo V: Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol 193: 80-87, 2001.
30. Camby I, Belot N, Lefranc F, Sadeghi N, de Launoit Y, Kaltner H, Musette S, Darro F, Danguy A, Salmon I, Gabius HJ and Kiss R: galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 61: 585-596, 2002.
31. Camby I, Belot N, Rorive S, Lefranc F, Maurage CA, Lahm H, Kaltner H, Hadari Y, Ruchoux MM, Brotchi J, Zick Y, Salmon I, Gabius HJ and Kiss R: Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 11: 12-26, 2001.
32. Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY, Zhao S, Kong C, Richardson D, O'Byrne KJ, Giaccia AJ and Koong AC: galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23: 8932-8941, 2005.
33. Nagy N, Legendre H, Engels O, Andre S, Kaltner H, Wasano K, Zick Y, Pector JC, Decaestecker C, Gabius HJ, Salmon I and Kiss R: Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer 97: 1849-1858, 2003.
34. Agarwal D, Goodison S, Nicholson B, Tarin D and Urquidi V: Expression of matrix metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with the absence of metastasis in an isogenic human breast cancer model. Differentiation 71: 114-125, 2003.
35. de Wit NJ, Burtscher HJ, Weidle UH, Ruiter DJ and van Muijen GN: Differentially expressed genes identified in human melanoma cell lines with different metastatic behaviour using high density oligonucleotide arrays. Melanoma Res 12: 57-69, 2002.
36. de Vries TJ, Trancikova D, Ruiter DJ and van Muijen GN: High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. Br J Cancer 78: 1156-1161, 1998.
37. Fang D, Hallman J, Sangha N, Kute TE, Hammarback JA, White WL and Setaluri V: Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma. Am J Pathol 158: 2107-2115, 2001.
38. Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P and Guerry D: Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 23: 8048-8056, 2005.
39. Ramsay JA, From L, Iscoe NA and Kahn HJ: MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol 105: 22-26, 1995.
40. Ilmonen S, Hernberg M, Pyrhonen S, Tarkkanen J and Asko-Seljavaara S: Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma. Melanoma Res 15: 375-381, 2005.